IL32 and COVID-19: This prospective, observational single-center study (1) examined levels of IL-32 and IL-34 at hospital admission in a sizeable cohort of patients with COVID-19 for the first time, (2) found no association between IL-32/IL-34 and CV disease in the context of COVID-19 and (3) disproved a correlation between IL-32/IL-34 and outcome, while a higher CV disease burden predicted short-term mortality in hospitalized patients with COVID-19.